Triferic AVNU
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Deficiency Anemia
Conditions
Iron Deficiency Anemia
Trial Timeline
Nov 30, 2021 → May 30, 2022
NCT ID
NCT05110768About Triferic AVNU
Triferic AVNU is a phase 2 stage product being developed by Rockwell Medical for Iron Deficiency Anemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT05110768. Target conditions include Iron Deficiency Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05110768 | Phase 2 | UNKNOWN |
| NCT04689932 | Approved | Completed |
Competing Products
20 competing products in Iron Deficiency Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| H. pylori treatment | Eisai | Phase 2/3 | 65 |
| Deferasirox | Novartis | Phase 3 | 77 |
| CSJ137 + Placebo | Novartis | Phase 1 | 33 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 65 |
| Desferasirox | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 52 |
| deferasirox | Novartis | Approved | 85 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 41 |
| ICL670 | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 76 |